Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine - Test2 - elhamkhani - TriplyDB

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

http://www.wikidata.org/entity/Q35206695

about

Prospects for dengue vaccines for travelers The dengue vaccine pipeline: Implications for the future of dengue control Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Vaccines and immunization strategies for dengue prevention Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination Dengue research opportunities in the Americas Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination Current progress in dengue vaccines Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys Immune correlates for dengue vaccine development Utility, limitations, and future of non-human primates for dengue research and vaccine development Dengue vaccines: recent developments, ongoing challenges and current candidates.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation Animal models of dengue virus infection Challenges in reducing dengue burden; diagnostics, control measures and vaccines.Developing a dengue vaccine: progress and future challenges.RNA-based viral vectors.Recent progress in dengue vaccine development.Development of Peptide Vaccines in Dengue.The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.Dengue Vaccine: The Need, the Challenges, and Progress.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.Zika Virus Vaccine Development.Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Dengue vaccine development: challenges and emerging opportunities

P2860

Q26314423-7F0FCD22-A428-4F09-97E3-C0662C53527B Q26314683-2262A154-03A1-4325-BBC7-CD5DD7FE2581 Q27654848-84D4DDC4-C962-407A-8F38-9AD48DC4E7B0 Q28077521-C7B5623B-391E-49A2-A2B2-BD08B3B9C36A Q28114614-1923C1FD-B2BF-4CA1-A375-6EBE6C1BB184 Q28656204-D1BB2EEA-9CDD-4965-AC20-4CF246F5BC26 Q28729784-1A5EAAD9-8793-4EBB-AE40-92AE8F328184 Q30250977-2DB4C4E3-FF70-41FE-9633-9B0CF32E43A7 Q33408300-D510F9F8-052C-4800-9AD5-0A0DFA8AFA51 Q33800244-AE253AE3-6DF4-4A42-A0BC-0E229742EAE1 Q33924674-0ED484B4-5078-41CC-886D-A76B6F534633 Q34238916-78EB7118-79BF-4D2D-AADF-C4D1EADCD2F6 Q34367194-C5A3F3E0-EFCC-4382-B7FA-ABE52BEBDCD1 Q35069160-2D987791-98D0-43E2-B444-20719EA50D10 Q35548048-66DE9CDF-7F98-4CE5-B734-18A3FDF5C789 Q36181531-11A8476D-B92A-4C7A-9045-CA4DCECFF96D Q36205859-9C4DEDD4-D609-4724-9587-409E8AA885F8 Q36607295-FF7BC2C3-2FE5-4C71-AE29-D804FD72548B Q36667964-AF4AB815-0F96-4367-A11C-23B38DEE2F23 Q36756643-844A92A2-EDBE-45E9-B7BE-0A62193542D1 Q36846290-9E294BCC-4AB3-4202-AFEB-0DF31601CAF1 Q37115807-648D5E4D-767B-459E-8611-EEC4763C7C43 Q37184768-AFB4901D-62E6-4E15-83F5-6277B789259F Q37706823-B6DAA788-5634-4A88-8808-F634002E6284 Q37987131-9A7DBD6C-5C54-4F99-B528-F7519F68F465 Q38140035-050B4797-8A24-4DB1-A170-ACF13FBAC356 Q38201151-E997D461-DB7E-407A-8AAA-C8FDC3D49624 Q38266413-7A84E2C7-48F1-42BF-B5F5-6E21EFB62FD9 Q38303232-1499AC9D-6CA2-4B4D-BD60-87807B066607 Q40038715-B9AB386F-3AE6-4BE8-B7FB-10E8D4B40BE3 Q40109446-F3DF16D4-43C5-4B89-A403-FEFFCF7A775B Q40116968-8731E392-DC66-43C4-97E0-9C722F35988D Q42336350-703B5680-BC80-45F3-89F1-C11863FFD0FB Q42985743-A96927B3-7E5E-4E15-BBC2-59F5A3B20C3A Q45323668-7132FD61-7161-4F1E-84DA-21AE2A23FB61 Q47006432-22E6A734-FBEA-407F-8711-4190E6EDCAF7 Q47570091-8A1BF083-E9BC-4778-9284-3659EA67286B Q53158319-32EC3D98-EC07-4189-B228-0B2EC52E7B5C

P2860

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

http://www.wikidata.org/entity/Q35206695

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Development and clinical evalu ...... uated tetravalent DENV vaccine

@ast

Development and clinical evalu ...... uated tetravalent DENV vaccine

@en

type

label

Development and clinical evalu ...... uated tetravalent DENV vaccine

@ast

Development and clinical evalu ...... uated tetravalent DENV vaccine

@en

prefLabel

Development and clinical evalu ...... uated tetravalent DENV vaccine

@ast

Development and clinical evalu ...... uated tetravalent DENV vaccine

@en

P1433

Q35206695-36139ADC-8DD4-46FE-8FBB-27135BB33489

P1476

Q35206695-DD004058-675E-48CA-88D2-8EF3A8C6A8E0

P2093

Q35206695-31502BCB-ABBB-44DA-A65A-439BE468DC33

Q35206695-B3F71B94-3E08-4EA9-92EF-93EA3441EB92

Q35206695-B6925E29-B2DC-496D-8278-8E1F28965E96

P2860

Q35206695-0616A620-AC56-43F7-A287-0CA8478C71C8

Q35206695-0B479691-C388-4932-9484-BDD2BCA01305

Q35206695-0E260064-FE73-4736-91DC-87ECF1E1456F

Q35206695-1705CA00-19C8-43A8-96E2-55BBA7F3CDDB

Q35206695-1993B457-5410-442B-8A45-0C3B2EF5023C

Q35206695-1AEA782C-A9E3-4C88-89FB-617E1B0C6029

Q35206695-2C20B49C-A75C-44F5-BC12-478EFCC16D5D

Q35206695-2FB2DE13-9529-48FE-B894-90638A826E23

Q35206695-33BA59BF-DEA5-4743-A71B-EA9DDA462716

Q35206695-36FCB5BE-DB27-4D6B-9E40-71C6D3DE0504

P304

Q35206695-18C5DF95-AD72-4379-9548-4B442321855B

P31

Q35206695-6F0F0A3F-1654-4BA1-A0A6-965ED9F74DF3

P356

Q35206695-57F9C92A-6BAB-40D8-9570-5D5D08DFDF4B

P407

Q35206695-648881A8-A74F-441F-A36C-6746BD98251A

P433

Q35206695-274CB704-B169-4C0B-9D9E-B903EA38440C

P478

Q35206695-0CE10B53-6664-4612-930C-629CAD55A8F9

P50

Q35206695-09356098-8D61-4680-A832-D1D2FAE7E5F9

Q35206695-09825B19-5C37-4F69-B9DB-1051431910DB

P577

Q35206695-DF3DA4A0-DEEC-41D1-9F76-3B41A3A9F118

P5875

Q35206695-9F533922-DC58-4E01-B6E3-D6C0010EA0AB

P698

Q35206695-8F8D95DA-008B-4465-AB0A-27C3F89C9303

P921

Q35206695-F1D26C45-FC95-43B3-9BB7-8F5196F36239

P932

Q35206695-196F1A26-404B-4876-9CBA-C4A79F4F725D

P356

J.VACCINE.2011.07.023

P1433

P1476

Development and clinical evalu ...... uated tetravalent DENV vaccine

@en

P2093

Alexander C Schmidt

http://www.w3.org/2001/XMLSchema#string

Beth D Kirkpatrick

http://www.w3.org/2001/XMLSchema#string

Kristen K Pierce

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

A prospective study of dengue infections in Bangkok

P304

7242-7250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2011.07.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Stephen S Whitehead

P577

2011-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51514325

http://www.w3.org/2001/XMLSchema#string

P698

21781997

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

3170437

http://www.w3.org/2001/XMLSchema#string